Weighing the risks and benefits
The PSA test is a screening test for prostate cancer. Screening tests aim to find cancer in people before they have symptoms. Screening can help find cancers at an earlier stage, when they are possibly easier to treat. If prostate cancer is found early as a result of screening, it could seem like PSA testing would always be a good idea. However, it is important to understand the risks and benefits of testing to decide if it is right for you. The choice to do a PSA test is an individual decision that should be made after understanding the risks and benefits of testing.
Benefits of PSA testing:
- Can detect prostate cancer before you have any symptoms
- Can detect a fast growing cancer at an early stage, before it spreads to other parts of the body and becomes difficult to treat
Doctors are still studying whether PSA testing lowers the risk of death from prostate cancer. Current study results on the benefits of screening are conflicting, which is why the choice to do a PSA test should be a personal one.
Results from a large European study of prostate cancer screening found that men who had prostate-specific antigen (PSA) testing had a 20 percent lower chance of dying from prostate cancer after 13 years, compared with men who did not have prostate cancer screening (Hugosson et al., 2019). However, the study also showed that 781 men would need to prevent one death from prostate cancer (Schröder et al., 2014). This means that testing the general population involves many men getting tested, and a very small number benefitting.
Risks of PSA testing:
Inaccurate test results
There is a chance of a false positive test result with all screening tests. This means that your PSA level is elevated but no cancer is present. A false-positive test result may create anxiety for you and your family, or lead to additional invasive medical procedures with their own side effects, such as a prostate biopsy. As multiple factors can cause PSA levels to rise, false positive PSA test results are common; approximately 25% of people who have a prostate biopsy due to an elevated PSA level are found to have prostate cancer after biopsy (Lopez-Corona et al., 2007).
A false negative test result means that the PSA level is found to be normal when prostate cancer is present. Approximately 15% of individiuals with prostate cancer do not have elevated PSA levels (Prostate Cancer UK, 2021). A false negative test result may provide false reassurance that no cancer is present. If you are experiencing prostate-related symptoms despite a normal PSA level, always contact your GP.
Overdiagnosis and overtreatment
Overdiagnosis means diagnosing a condition that would never pose a threat to your health or life. Overdiagnosis can lead to treatments that are not necessary and have their own side effects, known as overtreatment. This can result in an individual sustaining harms with no benefits from screening for a disease. Research estimates 23% 43% of prostate cancers that are diagnosed with PSA testing may never need to be treated and will not affect a man’s life expectancy (Sandhu & Andriole, 2012). This means that many men die “with” prostate cancer, rather than “from” prostate cancer. However, most men who are diagnosed with prostate cancer understandably want to pursue treatment. Unnecessary testing and treatment can cause side effects such as incontinence, pain, and erectile dysfunction.